在弥漫性大B细胞淋巴瘤患者中，FcγRIIIA和FcγRIIA基因多态性与利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松（CHOP）方案治疗的反应无关。
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
作者信息
Mitroviç Zdravko, Aurer Igor, Radman Ivo, Ajdukoviç Radmila, Sertiç Jadranka, Labar Boris
机构信息
Division of Hematology, Department of Internal Medicine, University Hospital Center and Medical School University of Zagreb, Croatia.
出版信息
Haematologica. 2007 Jul;92(7):998-9. doi: 10.3324/haematol.10327.
We investigated the association ofFcgammaRIIIaa and FcgRIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcgammaRIIIa and FcgRIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via FcgammaRIIIa and FcgammaRIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.
我们研究了58例弥漫性大B细胞淋巴瘤（DLBCL）患者中FcγRIIIa和FcγRIIa基因多态性与R-CHOP治疗反应之间的关联。FcγRIIIa和FcγRIIa基因多态性不影响反应、无事件生存期或总生存期。这些结果表明，通过FcγRIIIa和FcγRIIa的抗体依赖细胞介导的细胞毒性（ADCC）可能不是R-CHOP方案在DLBCL中发挥作用的主要机制。
Zotero 插件